Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of rVSV∆G-SUDV-GP Vaccine in Healthy Adults
NCT07565090Phase 1Recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Sudan virus disease (SVD) comparing rVSVΔG-SUDV-GP with Placebo (2 arms). Primary endpoints: Safety and tolerability: solicited reactogenicity at 14 days, Safety and tolerability: unsolicited reactogenicity at 28 days and 1 more. Started May 2026; status: recruiting.
02
Drugs
rVSV-SUDV-GP
03
Conditions
Sudan virus disease (SVD)
Beyond the preview
Go deeper on NCT07565090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565090.